Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry - Final Guidance
FDA-2020-D-1079-0064Other
Comments
7
Last activity Jun 22, 2026
Deadline
--
Net supportiSupport minus oppose · campaigns included
0%
0% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry - Final Guidance
- Posted
- Jan 24, 2023
- Comment period
- Jan 24, 2023 – ?
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
0%
Net support
Support2Oppose2Other3
Aggregates include form-letter campaigns. Excluding them, net support is 0% across organic comments.
Who commented
Breakdown by commenter type.
Individual
6
Advocacy
1
Comments over time
Weekly arrivals, stacked by stance.
Posted Jan 24, 2023
Jan 23Oct 7Oct 27Mar 16May 25Jun 22
Support2Oppose2Other3
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
33%
33%
33%
Advocacy
0%
0%
100%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Jun 22, 2026Comment from randy MilesOtherIndividualRead comment →
- Oct 8, 2024Comment from Herb’d IngestiblesOpposeIndividual
The commenter opposes the requirement for a New Drug Application (NDA) for cannabis-derived products, arguing that the regulatory burden is based on prejudice rather than science. They also argue that the government fails to acknowledge that these products are intended for adult use and that there is a lack of evidence regarding specific harm to minors.
Read comment →